Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications.

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease caused by mutations in sarcomeric contractile proteins, characterized by cardiomyocytes disarray, interstitial fibrosis, increased arteriolar wall thickness and scarring. Fibrosis could represent a substrate for the generation of mali...

Full description

Bibliographic Details
Main Author: Carla Contaldi
Format: Article
Language:English
Published: Barcaray International 2016-01-01
Series:International Cardiovascular Forum Journal
Subjects:
Online Access:http://icfjournal.org/index.php/icfj/article/view/253/Contaldi%20253%20pp3-9.pdf
id doaj-2f8f5a21649447eaa5c20d5824c37aee
record_format Article
spelling doaj-2f8f5a21649447eaa5c20d5824c37aee2020-11-24T22:51:47ZengBarcaray InternationalInternational Cardiovascular Forum Journal2410-26362409-34242016-01-01839https://doi.org/10.17987/icfj.v8i0.253Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications.Carla Contaldi0Department of Advanced Biomedical Sciences, Federico II University School of Medicine of Naples, Italy.Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease caused by mutations in sarcomeric contractile proteins, characterized by cardiomyocytes disarray, interstitial fibrosis, increased arteriolar wall thickness and scarring. Fibrosis could represent a substrate for the generation of malignant ventricular tachyarrhythmias, which represent the current pathway for sudden cardiac death and is responsible for passive diastolic dysfunction, that is the leading cause of dyspnea. The aim of this review is to depict the increasingly role of cardiac magnetic resonance (CMR) for assessment of myocardial fibrosis in HCM. This article will briefly review the current status of the novel CMR techniques (the Late Gadolinium Enhancement and the emerging T1 mapping) for identification, characterization and quantization of myocardial fibrosis in HCM. In addition, this review will discuss the most recent acquisition techniques, the new parameters and their possible clinical utility in diagnosis, therapeutic management and prognosis in HCM.http://icfjournal.org/index.php/icfj/article/view/253/Contaldi%20253%20pp3-9.pdfMyocardial fibrosisLate Gadolinium EnhancementT1-mappingHypertrophic cardiomyopathy
collection DOAJ
language English
format Article
sources DOAJ
author Carla Contaldi
spellingShingle Carla Contaldi
Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications.
International Cardiovascular Forum Journal
Myocardial fibrosis
Late Gadolinium Enhancement
T1-mapping
Hypertrophic cardiomyopathy
author_facet Carla Contaldi
author_sort Carla Contaldi
title Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications.
title_short Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications.
title_full Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications.
title_fullStr Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications.
title_full_unstemmed Assessment of Myocardial Fibrosis in Hypertrophic Cardiomyopathy by Cardiac Magnetic Resonance: Modalities and Clinical Applications.
title_sort assessment of myocardial fibrosis in hypertrophic cardiomyopathy by cardiac magnetic resonance: modalities and clinical applications.
publisher Barcaray International
series International Cardiovascular Forum Journal
issn 2410-2636
2409-3424
publishDate 2016-01-01
description Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease caused by mutations in sarcomeric contractile proteins, characterized by cardiomyocytes disarray, interstitial fibrosis, increased arteriolar wall thickness and scarring. Fibrosis could represent a substrate for the generation of malignant ventricular tachyarrhythmias, which represent the current pathway for sudden cardiac death and is responsible for passive diastolic dysfunction, that is the leading cause of dyspnea. The aim of this review is to depict the increasingly role of cardiac magnetic resonance (CMR) for assessment of myocardial fibrosis in HCM. This article will briefly review the current status of the novel CMR techniques (the Late Gadolinium Enhancement and the emerging T1 mapping) for identification, characterization and quantization of myocardial fibrosis in HCM. In addition, this review will discuss the most recent acquisition techniques, the new parameters and their possible clinical utility in diagnosis, therapeutic management and prognosis in HCM.
topic Myocardial fibrosis
Late Gadolinium Enhancement
T1-mapping
Hypertrophic cardiomyopathy
url http://icfjournal.org/index.php/icfj/article/view/253/Contaldi%20253%20pp3-9.pdf
work_keys_str_mv AT carlacontaldi assessmentofmyocardialfibrosisinhypertrophiccardiomyopathybycardiacmagneticresonancemodalitiesandclinicalapplications
_version_ 1725668666952908800